** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34
** Wall Street brokerages start coverage of the drug developer on a bullish note as IPO research quiet period ends
** J.P. Morgan starts coverage with "overweight" rating and $30 PT, a 177.2% upside to the stock's last close
** "With data for MZE829 available, we see its potential in addressing a wide population, competitive pricing, market share, and high success probability as key factors for boosting MAZE shares" - J.P. Morgan analysts referring to co's kidney disease therapy candidate
** Leerink Partners starts coverage with "outperform" rating and PT of $28, a 158.8% upside to the stock's last close
** "Chronic kidney disease represents a significant market opportunity, especially considering the major drain on overall Medicare spending. We assume gross peak sales of ~$1.8B in CKD" - Leerink Partners
** J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities were the underwriters for the IPO
** Stock has fallen 32% since its Nasdaq debut in January
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。